Ebola vaccine trial begins in DR Congo

WHO announced the start of the Tumaini trial in the Democratic Republic of Congo, with first doses of Ervebo given to assess cross-protection against Bundibugyo Ebola. The outbreak has caused more than 9,700 infections and 4,600 deaths. The trial uses a ring vaccination strategy and will later add two candidates, Oxford's ChAdOx1 and Moderna's mRNA vaccine. It includes children aged 12 and older and pregnant women, generating evidence for often-excluded populations.